MRSN Live signals | Maximize Profits with Getagraph.com

BUY 135632 min ago

@ $3.79

Issued: 14 Feb 2024 @ 13:46

Return: -27.97%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: -3.33 %

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Stats
Today's Volume	2.50M
Average Volume	2.18M
Market Cap	334.05M
EPS	$0 ( 2024-05-09 )
Next earnings date	( $-0.170 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.44
ATR14	$0.00900 (0.33%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Alleva Lawrence M	Buy	3 996	Stock Option (right to buy)
2024-01-13	Mandelia Ashish	Buy	0
2024-01-15	Protopapas Anna	Buy	17 708	Common Stock
2024-01-15	Protopapas Anna	Buy	21 250	Common Stock
2024-01-16	Protopapas Anna	Sell	29 399	Common Stock

INSIDER POWER
74.96
Last 98 transactions
Buy: 4 017 838 \| Sell: 585 969

Volume Correlation

Long: -0.04 (neutral)

Short: 0.86 (strong)

Signal:(46.99) Same movement expected

Mersana Therapeutics Inc Correlation

10 Most Positive Correlations
MRUS	0.888
FULC	0.886
REYN	0.884
REGN	0.884
CSX	0.881
CREX	0.879
BFIT	0.878
CBIO	0.876
ENSG	0.875
ALRM	0.873

10 Most Negative Correlations
SVOK	-0.889
RTPY	-0.883
RAAC	-0.871
VALN	-0.868
KVSB	-0.86
GHVI	-0.849
SPCB	-0.848
RELL	-0.844
AMTI	-0.841
MFNC	-0.837

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mersana Therapeutics Inc Correlation - Currency/Commodity

0.04
( neutral )

0.00
( neutral )

-0.48
( neutral )

Mersana Therapeutics Inc Financials

Annual	2023
Revenue:	$36.86M
Gross Profit:	$35.34M (95.88 %)
EPS:	$-1.480

FY	2023
Revenue:	$36.86M
Gross Profit:	$35.34M (95.88 %)
EPS:	$-1.480

FY	2022
Revenue:	$26.58M
Gross Profit:	$25.65M (96.51 %)
EPS:	$-2.22

FY	2021
Revenue:	$43 000.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.37

Financial Reports:

No articles found.

Mersana Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Mersana Therapeutics Inc

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.